期刊文献+

硫糖铝在体外对抗幽门螺杆菌HpaA IgY的保护作用评价 被引量:3

Evaluation on Protective Effects of Sucralfate on Anti-H.pylori HpaA IgY in Vitro
暂未订购
导出
摘要 目的评价硫糖铝对HpaA IgY的保护作用,为制备IgY口服制剂奠定基础。方法大量诱导工程菌DH5α-HpaA-pQE30,制备纯化的重组蛋白HpaA。以HpaA为抗原接种洛曼母鸡,制备纯化的IgY。在不同pH值、含不同浓度胃蛋白酶的HpaA IgY液中加入不同浓度的硫糖铝;将IgY液反复冻融;以ELISA法测定HpaA IgY的剩余抗体活性(AR/AC)。结果在pH 1.5条件下,60%硫糖铝可使IgY抗体剩余活性维持65.8%;在pH 2.0条件下,含30%硫糖铝的IgY可使抗体活性维持85.4%,含50%硫糖铝的IgY可完全维持抗体活性。在pH 3.0条件下,含30%硫糖铝的IgY可使抗体活性维持87.3%,而含40%以上硫糖铝的IgY几乎可完全维持抗体活性。在胃蛋白酶浓度0.02mg/mL条件下,当含10%、30%、50%硫糖铝IgY的剩余活性,在pH值2.0时,分别为62.8%、71.6%、82.5%;在pH值3.0时,分别为75.6%、87.4%、94.5%;反复冻融后,含10%硫糖铝的IgY可使抗体活性提高到70.6%,含30%硫糖铝可使IgY的抗体活性提高到82.7%,50%硫糖铝可提高到89.3%。结论 30%以上的硫糖铝可增强VacA IgY对低pH和胃蛋白酶的耐受能力,抗冻融能力,是较理想的IgY保护剂。 Objective To evaluate the protective effects of sucralfate on anti-H.pylori HpaA immunoglobulin yolk(HpaA IgY) and provide experimental basis for preparation of IgY by oral administration.Method The recombinant protein HpaA was expressed in engineering bacteria DH5α-HpaA-pQE30 and purified.HpaA IgY was prepared by inoculating purified HpaA in Lohman hen and then depurated.Sucralfate of different concentration was added into HpaA IgY under different pH(1.0-3.0) and contained different concentration of pepsin,and was enforced with freeze thawing.The residuary antibody activity(AR/AC%)of IgY was determined by the method of ELISA.Results The activity of HpaA IgY containing 60% sucralfate could keep its activity at 65.8% under pH 1.5.The activity of IgY containing 30% sucralfate could keep its activity at 85.4% while 50% sucralfate could completely keep its activity under pH 2.0.Under pH 3.0,30% sucralfate could remain its activity at 87.3% while sucralfate above 40% completely protected its activity.As the concentration of pepsin was 0.02mg/mL,the residuary antibody activity of IgY containing 10%,30%,50% sucralfate were 62.8%,71.6%,82.5% under Ph 2.0 and 75.6%,87.4%,94.5% under pH 3.0.After enforced with freeze thawing 10%,30%,50% sucralfate may make the residuary antibody activity of IgY increase to 70.6%,82.7% and 89.3%.Conclusion HpaA IgY containing 30% or above sucralfate can improve the tolerance of IgY against low pH,pepsin and freeze thawing intervention.It shows that sucralfate is a satisfactory protectant for HpaA IgY.
出处 《中国医药指南》 2011年第6期5-7,共3页 Guide of China Medicine
基金 重庆市科委(CSTC 2005EA5020)
关键词 幽门螺杆菌 重组蛋白HpaA 卵黄抗体 硫糖铝 抗体活性 Helicobacter pylori Recombinant HpaA Immunoglobulin yolk Sucralfate Antibody activity
  • 相关文献

参考文献4

二级参考文献19

  • 1莫剑忠,王承党,王少先,朱翠英,朱志仁,欧阳春,萧树东,袁济民,张德中,江绍基.健康成人餐后胃内食物分布和排空的研究──应用双核素标记试餐及SPECT技术[J].中华消化杂志,1995,15(4):215-217. 被引量:9
  • 2柯美云,蓝宇,王智风,邢进宏.功能性消化不良昼夜胃内pH变化[J].临床消化病杂志,1995,7(3):97-100. 被引量:13
  • 3胡伏莲,黄志烈,王菊梅,贾博琦,刘新光,谢鹏雁.幽门螺杆菌的根除及其在十二指肠溃疡愈合和复发中的作用[J].中华消化杂志,1996,16(2):106-107. 被引量:109
  • 4F奥斯伯 颜子颖译.精编分子生物学实验指南[M].北京:科学出版社,1998.671.
  • 5Hocking D, Webb E, Redcliff F, et al. Isolation of recombinant protective Helicobacter Pylori antigen. Infect Immun, 1999, 67 (9):4713 - 4719.
  • 6International agency for reseach on cancer. Schistosomes, liver fluker and Helicobacter Pylori. IARC monographs on the evalition on carcinogenic risks to human. Vo161, Lyon: IASC, 1994.
  • 7Pounder RE, Ng D.The prevalence of Helicobacter Pylori infection in different countries, science, 1995, 267:17.
  • 8Evens DG, Evans DJ Jr, Lampert HC, et al. Restriction fragment length polymorphism in the adhesin gene hpaA of Helicobacter pylori.Am J Gastroenterol, 1995, 90(8): 1282 - 1288.
  • 9Jones AC, Logan RP, Foynes S, et al. A flagellar sheath protein of Helicobacter pylori is identical to HpaA, a putative N- acetylneuraminyllactose- binding hemagglutinin, but is not an adhesin for AGS cells. J Bacterol, 1997,179(17), 5643 - 5647.
  • 10Kuo CH, Wu DC, Lu CY, et al. The media of rapid urease test influence the diagnosis of Helieobacter pylori. Hepatogastroenterology,2002, 49:1191 - 1194.

共引文献18

同被引文献30

  • 1张长青,张葵玲.硫糖铝混悬液与片剂治疗胃溃疡疗效比较[J].广东医学,2005,26(7):996-997. 被引量:5
  • 2陈士葆,沈云芳,陈惠君,茅关兴,郭文荣.硫糖铝治疗消化性溃疡[J].新药与临床,1996,15(1):11-13. 被引量:15
  • 3成虹,胡伏莲,李江.幽门螺杆菌耐药性对其根除治疗影响的研究[J].中华医学杂志,2006,86(38):2679-2682. 被引量:97
  • 4GRAHAM D Y, SHIOTANI A. New concepts of resistance in the treatment of Helicobacter pylori infections [ J ]. Nat Clin Pract Gastr, 2008, 5: 321-331.
  • 5MALFERTHEINER P, MEGRAUD F, O'MORAIN C, et al. Current concepts in the management of Helicobacter pylori infec- tion : The maastricht Щ consensus report [ J ]. Gut, 2007, 56 : 772-781.
  • 6GISBERT J P, GISBERT J L, MARCOS S, et al. Empirical res- cue therapy after ltelicobacter pylori treatment failure : A lO-year single-centre study of 500 patients [ J]. Aliment Pharm Therap, 2008, 27(4) : 346-354.
  • 7HANS K, DAVID C, HANNE O, et al. Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with eystie fibrosis : A phase I feasibility study [ J ] . Pediatr Pulmonol, 2003, 35 ( 6 ) : 432-440.
  • 8WORLEDGE K L, GODISKA R, BARRETT? T A, et al. Oral administration of avian tumor necrosis factor antibodies effectively treats experimental colitis in rats [ J]. Dig Dis Sei, 2000, 45 (12) : 2298-2305.
  • 9LI X Y, JIN L J, TIM A M, et al. Chitosan-alginate microcap- sules for oral delivery of egg yolk immunoglobulin (IgY) [ J ]. J Agric Food Chem, 2007, 55(8) : 2911-2917.
  • 10SHEN C H. The research of water-soluble drug microencapsula- tion and release characteristic [ D ]. Chongqing: Chongqing Uni- versity, 2003.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部